November 4, 2025 — Leads & Copy —
Guardant Health (Nasdaq: GH) announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock. Underwriters will have a 30-day option to purchase up to an additional $37.5 million of shares. The offering’s completion is subject to market conditions.
Goldman Sachs & Co. LLC, Jefferies, Leerink Partners and Guggenheim Securities are joint book-running managers for the offering.
Guardant Health intends to use the net proceeds from the stock offering, together with the net proceeds from its concurrent convertible notes offering, for general corporate purposes, which may include repurchasing a portion of its 0% convertible senior notes due 2027. Corporate purposes may also include acquisitions, but there are currently no agreements or commitments for such transactions.
Concurrently, Guardant Health intends to offer $300.0 million aggregate principal amount of its Convertible Senior Notes due 2033 to qualified institutional buyers. Initial purchasers will have an option to purchase up to an additional $45.0 million aggregate principal amount of notes. The stock offering is not contingent on the notes offering, and vice versa.
The stock offering will be made pursuant to a shelf registration statement filed with the SEC on May 22, 2023.
Copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: (866) 471-2526, or by emailing prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, telephone: (877) 821-7388, or by emailing prospectus_department@jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: (800) 808-7525, ext. 6105, or by emailing syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: at (212) 518-9544, or by emailing GSEquityProspectusDelivery@guggenheimpartners.com.
About Guardant Health
Guardant Health is a precision oncology company focused on guarding wellness and giving every person more time free from cancer.
Source: Guardant Health
